Cambridge, UK--(Marketwire - June 28, 2007) -
For immediate release 28 June 2007
ABCAM PLC
("Abcam" or "the Company")
Year-end Trading Update
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that
markets antibodies via its own online catalogue, is pleased to announce a
trading update ahead of its results for the year ending 30 June 2007.
Sales in the second half have continued their strong growth trend with the
result that the Company expects full-year sales to slightly exceed market
expectations. Due to the stronger sales, together with slightly lower expenses,
pre-tax profits will exceed market expectations by about 10 per cent.
Abcam now has more than 33,000 products in its online catalogue, compared with
23,200 at 30 June 2006. The Company is pleased to report that construction of
its high-throughput production facility in Cambridge was completed on schedule
and that operations have commenced. The facility, which is one of the world's
most advanced antibody production laboratories, is designed to produce an
increasing number of higher margin in-house products to add to Abcam's online
catalogue.
It is expected that Abcam's results for the year ending 30 June 2007 will be
announced in mid September 2007.
For further information please contact:
Abcam + 44 (0) 1223 696000
Jonathan Milner, Chief Executive Officer
Eddie Powell, Chief Financial Officer
www.abcam.com
Numis Securities + 44 (0) 20 7776 1500
Michael Meade
James Black
Buchanan Communications + 44 (0) 20 7466 5000
Mark Court / Mary-Jane Johnson
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered
in Cambridge, UK, with a US office located in Cambridge, Massachusetts. Abcam
was admitted to AIM in November 2005 and trades under the ticker symbol ABC.
The Company produces and distributes its own and third party produced antibodies
to academic and commercial users throughout the world with product information
provided and ordering available through the Company's website,
www.abcam.com.
The antibodies are sold under the Abcam brand name. The Company's vision is to
build the largest online antibody resource in the world while also ensuring that
the antibodies are of high quality and commercially viable. Abcam now has an
online catalogue of approximately 33,000 products, most of which are antibodies,
from over 200 suppliers supported by up-to-date and detailed technical data
sheets, which are created by the Company. The Company currently employs 120
staff in its three operating companies.
This information is provided by RNS
The company news service from the London Stock Exchange